FDA removes epinephrine from COVID-19 temporary compounding list

Hospital News

The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.

FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

Products You May Like

Articles You May Like

A Year of Crisis: How COVID-19 Upended the Election’s Focus on Health Care Policy—Or Did It?
CMS approves controversial Medicaid waiver in Nebraska, creating 2-tiered system
Supply chain pains: How Geisinger, Sutter and Intermountain are prepping for flu season
CMS to delay start date for radiation oncology model, as urged by AHA
Poll: Most Americans Say President Trump is Intervening with the FDA’s and CDC’s Coronavirus Work, But Trust the Agencies at Least a Fair Amount to Do the Right Thing

Leave a Reply

Your email address will not be published. Required fields are marked *